Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia

K Schmiegelow; E Forestier; M Hellebostad; Martin Heyman Donovan; J Kristinsson; S Söderhäll; M Taskinen; Nordic Society of Paediatric Haematology and Oncology

doi:10.1038/leu.2009.251

Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia

K Schmiegelow, E Forestier, M Hellebostad, Martin Heyman Donovan, J Kristinsson, S Söderhäll, M Taskinen, Nordic Society of Paediatric Haematology and Oncology

Department of Paediatrics and Adolescent Medicine

335 Citations (Scopus)

Abstract

Analysis of 2668 children with acute lymphoblastic leukemia (ALL) treated in two successive Nordic clinical trials (Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 and ALL-2000) showed that 75% of all patients are cured by first-line therapy, and 83% are long-term survivors. Improvements in systemic and intrathecal chemotherapy have reduced the use of central nervous system (CNS) irradiation to

Original language	English
Journal	Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Volume	24
Issue number	2
Pages (from-to)	345-54
Number of pages	10
DOIs	https://doi.org/10.1038/leu.2009.251
Publication status	Published - 1 Feb 2010

Access to Document

10.1038/leu.2009.251

Cite this

Schmiegelow, K., Forestier, E., Hellebostad, M., Donovan, M. H., Kristinsson, J., Söderhäll, S., Taskinen, M., & Nordic Society of Paediatric Haematology and Oncology (2010). Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 24(2), 345-54. https://doi.org/10.1038/leu.2009.251

Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. / Schmiegelow, K; Forestier, E; Hellebostad, M et al.
In: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 24, No. 2, 01.02.2010, p. 345-54.

Research output: Contribution to journal › Journal article › Research › peer-review

Schmiegelow, K, Forestier, E, Hellebostad, M, Donovan, MH, Kristinsson, J, Söderhäll, S, Taskinen, M & Nordic Society of Paediatric Haematology and Oncology 2010, 'Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia', Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, vol. 24, no. 2, pp. 345-54. https://doi.org/10.1038/leu.2009.251

@article{a98ccda472e343839d9997c166f201e2,

title = "Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia",

abstract = "Analysis of 2668 children with acute lymphoblastic leukemia (ALL) treated in two successive Nordic clinical trials (Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 and ALL-2000) showed that 75\% of all patients are cured by first-line therapy, and 83\% are long-term survivors. Improvements in systemic and intrathecal chemotherapy have reduced the use of central nervous system (CNS) irradiation to ",

author = "K Schmiegelow and E Forestier and M Hellebostad and Donovan, \{Martin Heyman\} and J Kristinsson and S S{\"o}derh{\"a}ll and M Taskinen and \{Nordic Society of Paediatric Haematology and Oncology\}",

year = "2010",

month = feb,

day = "1",

doi = "10.1038/leu.2009.251",

language = "English",

volume = "24",

pages = "345--54",

journal = "Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K",

issn = "1476-5551",

publisher = "Springer Nature",

number = "2",

}

TY - JOUR

T1 - Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia

AU - Schmiegelow, K

AU - Forestier, E

AU - Hellebostad, M

AU - Donovan, Martin Heyman

AU - Kristinsson, J

AU - Söderhäll, S

AU - Taskinen, M

AU - Nordic Society of Paediatric Haematology and Oncology

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Analysis of 2668 children with acute lymphoblastic leukemia (ALL) treated in two successive Nordic clinical trials (Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 and ALL-2000) showed that 75% of all patients are cured by first-line therapy, and 83% are long-term survivors. Improvements in systemic and intrathecal chemotherapy have reduced the use of central nervous system (CNS) irradiation to

AB - Analysis of 2668 children with acute lymphoblastic leukemia (ALL) treated in two successive Nordic clinical trials (Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 and ALL-2000) showed that 75% of all patients are cured by first-line therapy, and 83% are long-term survivors. Improvements in systemic and intrathecal chemotherapy have reduced the use of central nervous system (CNS) irradiation to

UR - https://www.scopus.com/pages/publications/76749115697

U2 - 10.1038/leu.2009.251

DO - 10.1038/leu.2009.251

M3 - Journal article

C2 - 20010622

SN - 1476-5551

VL - 24

SP - 345

EP - 354

JO - Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K

JF - Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K

IS - 2

ER -

Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia

Abstract

Access to Document

Other files and links

Fingerprint

Cite this